抗精神病药治疗精神分裂症导致催乳素水平差异的机制
Mechanism of differences in prolactin levels in patients with schizophrenia after antipsychotics treatment

抗精神病药是目前精神分裂症的主要治疗手段，但药物治疗过程中不良反应发生率高，其中高催乳素血症相对常见。但不同患者在血清催乳素水平、临床症状上表现出明显的不同，临床个体差异大，存在很大争议。为进一步理解催乳素水平的异质性，该文从抗精神病药的多巴胺D2受体（dopamine D2 receptor, DRD2）阻断能力、透过血脑屏障的能力、与DRD2的亲和力、对DRD2的抑制/激动作用及个体间遗传多态性等方面阐述催乳素水平差异的机制。
：Antipsychotics have been the mainstay of schizophrenia treatment, but the frequency of adverse reactions (ARs) related with antipsychotics usage is high. Of all the ARs, hyperprolactinemia is relatively common and the controversy over it remains ongoing, as different patients manifest different prolactin levels and different clinical syndromes. Into understand this heterogeneity, this review stated the mechanisms underlying the different prolactin levels in schizophrenia patients after antipsychotics treatment, including the ability to block dopamine D2 receptor (DRD2), the influence on blood-brain barrier permeability, varying affinity toDRD2, the inhibition/excitatory effect on DRD2andgeneticpolymorphisms